Case Reports in Nephrology and Dialysis 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Posterior Reversible Encephalopathy Syndrome After Renal Transplant: A Simple Solution for a Complicated Patient
Conclusions: While the outcome of PRES is typically benign, a delay in diagnosis may lead to permanent neurologic deficits, and misdiagnosis can be lethal. The cornerstone of treatment is removal of the offending agent or treatment of the underlying etiology. A clinical picture of headache, visual abnormalities, altered mentation and seizures is sufficient to prompt an empiric discontinuation of agents known to cause PRES. Calcineurin inhibitors such as tacrolimus are known to cause PRES, and in our patient, discontinuation led to a complete clinical resolution.Case Rep Nephrol Dial 2015;5:20-25 (Source: Case Reports in Ne...
Source: Case Reports in Nephrology and Dialysis - November 7, 2014 Category: Urology & Nephrology Source Type: research
A Case Report on Allergic Rash Caused by Icodextrin
We report the case of a 23-year-old female who developed a skin rash following the use of icodextrin.Case Rep Nephrol Dial 2015;5:26-29 (Source: Case Reports in Nephrology and Dialysis)
Source: Case Reports in Nephrology and Dialysis - November 7, 2014 Category: Urology & Nephrology Source Type: research
Bucillamine-Induced Membranous Nephropathy with Crescent Formation in a Patient with Rheumatoid Arthritis: Case Report and Literature Review
Bucillamine is a disease-modifying antirheumatic drug that is structurally similar to D-penicillamine. The major renal side effect of bucillamine and D-penicillamine is proteinuria caused by membranous nephropathy (MN). In addition to MN, combined crescent formation has been occasionally reported in D-penicillamine-induced MN, while crescent formation has been rarely reported in bucillamine-treated cases. Here, we describe a 76-year-old female who presented with nephrotic syndrome and rapidly progressive glomerulonephritis. She was receiving bucillamine as initial treatment for recently diagnosed rheumatoid arthritis, and ...
Source: Case Reports in Nephrology and Dialysis - November 7, 2014 Category: Urology & Nephrology Source Type: research
